Use of Statins and Fracture
Open Access
- 26 January 2004
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 164 (2) , 146-152
- https://doi.org/10.1001/archinte.164.2.146
Abstract
The 3-Hydroxy-3-Methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are widely used medications for the treatment of hyperlipidemia.This publication has 17 references indexed in Scilit:
- Effects of 1-year treatment with fluvastatin or pravastatin on boneThe American Journal of Medicine, 2001
- Use of Statins and Risk of FracturesJAMA, 2001
- Effects of hormone replacement therapy on clinical fractures and height loss: the heart and estrogen/progestin replacement study (HERS)The American Journal of Medicine, 2001
- Oral statins and increased bone-mineral density in postmenopausal womenThe Lancet, 2000
- Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older womenThe Lancet, 2000
- Stimulation of Bone Formation in Vitro and in Rodents by StatinsScience, 1999
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Risk Factors for Increased Bone Loss in an Elderly Population The Rotterdam StudyAmerican Journal of Epidemiology, 1998
- Risk Factors for Hip Fracture in White WomenNew England Journal of Medicine, 1995
- Design of the Fracture Intervention TrialOsteoporosis International, 1993